Photodermatology, photoimmunology & photomedicine最新文献

{"title":"Persistent PhytoPhotoDermatitis Without Repeated Phytotoxin Exposure.","authors":"Sareena Gajebasia, Marese O'Reilly, Laura Surgenor, Emma Mack, Alyson Bryden, Kevin McKenna, Sally Ibbotson","doi":"10.1111/phpp.70120","DOIUrl":"10.1111/phpp.70120","url":null,"abstract":"","PeriodicalId":20123,"journal":{"name":"Photodermatology, photoimmunology & photomedicine","volume":"42 5","pages":"e70120"},"PeriodicalIF":2.7,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13541123/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148887432","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Beyond Tint: Active Ingredient Strategies for Post-Inflammatory Hyperpigmentation due to Visible Light in Skin of Color.","authors":"Willem Izak Visser, Husna Moola, Susanna Kannenberg, Bianca Tod, Henry W Lim","doi":"10.1111/phpp.70112","DOIUrl":"10.1111/phpp.70112","url":null,"abstract":"<p><strong>Background: </strong>Post-inflammatory hyperpigmentation (PIH) is among the most burdensome sequelae of inflammatory dermatoses in skin of color (SOC), and reduction of visible pigmentation represents the primary clinical outcome of interest. Tinted sunscreens containing iron oxides and/or pigmentary titanium dioxide are currently the best-evidenced strategy for preventing visible light-driven PIH in SOC. However, cosmetic unacceptability-including white cast, poor shade match, and texture incompatibility with acne-prone skin-significantly limits real-world adherence. This concept paper proposes a clinical reframing: when pigment-based visible light filters are not tolerated, pigmentation reduction may be achievable through proactive topical actives with direct anti-pigmentation activity.</p><p><strong>Methods: </strong>This commentary synthesizes the mechanistic and clinical literature on high-energy visible light (HEVL)-driven pigmentation in SOC, with particular focus on the opsin-3-MITF-melanogenesis axis and topical actives with demonstrated anti-pigmentation activity against HEVL-induced melanogenesis. Evidence is presented to support a proposed clinical reframing and pragmatic algorithm.</p><p><strong>Results: </strong>HEVL activates opsin-3 on melanocytes, upregulating MITF and promoting formation of stable, autophagy-resistant melanosomes-a mechanism distinct from UVA-driven photooxidation and particularly relevant in darker phototypes. Four prototypical actives with direct clinical or preclinical evidence against HEVL-induced pigmentation are reviewed.</p><p><strong>Conclusion: </strong>Pigmentation reduction-rather than the mechanism by which it is achieved-should be recognized as the primary clinical endpoint in photoprotection for PIH in SOC. When pigment-based visible light filters containing iron oxides and/or pigmentary titanium dioxide are cosmetically unacceptable, a strategy combining broad-spectrum UVA1 photoprotection with a topical active with anti-pigmentation activity represents a rational, evidence-informed alternative that keeps the clinical goal firmly in focus.</p>","PeriodicalId":20123,"journal":{"name":"Photodermatology, photoimmunology & photomedicine","volume":"42 4","pages":"e70112"},"PeriodicalIF":2.7,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13401449/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148593196","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Epidermal Permeability Barrier Dysfunction Influences Acute and Chronic Skin Responses to UVA and UVB Radiation.","authors":"Pan Wu, Piyan Hua, Qiuyan Yao, Zhenghui Yang, Ying Tu, Hua Gu","doi":"10.1111/phpp.70108","DOIUrl":"10.1111/phpp.70108","url":null,"abstract":"<p><strong>Background: </strong>The epidermal permeability barrier is crucial for skin homeostasis and defending against ultraviolet radiation. While it's known that barrier dysfunction is a feature of many dermatoses, how different degrees of barrier dysfunction affect acute and chronic responses to UVA and UVB remains unclear. This study compared erythema and pigmentation responses in skin with different levels of barrier dysfunction.</p><p><strong>Methods: </strong>Forty-nine healthy female subjects (Fitzpatrick skin types III-IV) were enrolled. Barrier-impaired models were created on one volar forearm by tape stripping; the contralateral forearm served as a control. Both sites received graded doses of UVA and UVB. Skin color was assessed using a spectrophotometer to obtain L* (lightness) and a* (redness) values. Changes (△L, △a) were compared between barrier-impaired and normal skin immediately, 24 h, and 2 weeks after irradiation.</p><p><strong>Results: </strong>The influence of skin barrier integrity on UVA-induced immediate pigment darkening varies with UVA dose: a more compromised barrier correlates with a stronger response at low doses, whereas normal skin exhibits a more pronounced reaction at higher doses. Moderate-to-severe barrier damage led to more pronounced persistent pigment darkening and delayed tanning after UVA. Following UVB exposure, severely impaired skin exhibited more pronounced delayed erythema and post-inflammatory hyperpigmentation than normal skin.</p><p><strong>Conclusion: </strong>An intact epidermal permeability barrier contributes to protecting the body from UV-induced damage. Therefore, restoring and maintaining an intact epidermal barrier should be considered a fundamental strategy in photoprotection and the clinical management of disorders associated with barrier dysfunction.</p>","PeriodicalId":20123,"journal":{"name":"Photodermatology, photoimmunology & photomedicine","volume":"42 4","pages":"e70108"},"PeriodicalIF":2.7,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13382186/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148520748","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Erlotinib and Leflunomide Disrupt 6-Formylindolo[3,2-b]Carbazole Metabolism and Sensitize Keratinocytes to UVA Radiation-Induced Apoptosis.","authors":"Frederick Hartung, Julien Dairou, Samhita Ramamoorthy, Katharina M Rolfes, Stephan Meller, Thomas Haarmann-Stemmann","doi":"10.1111/phpp.70099","DOIUrl":"10.1111/phpp.70099","url":null,"abstract":"<p><strong>Background/purpose: </strong>Phototoxicity is a common adverse effect triggered by systemic or topical drug treatments. It is mainly caused by drug-induced sensitization to UVA radiation, arising from either the drug's inherent photosensitizing potential or its interference with the metabolism of endogenous photosensitizers. A potent endogenous UVA sensitizer is 6-formylindolo[3,2-b]carbazole (FICZ), a tryptophan photoproduct formed in UVB-irradiated epidermal cells. By sequentially activating the aryl hydrocarbon receptor signaling pathway and inducing cytochrome P450 (CYP) 1A1 expression, FICZ induces its own degradation. Recently, we reported that the BRAF inhibitor vemurafenib interferes with CYP1A1 activity and sensitizes keratinocytes to FICZ/UVA-induced phototoxicity. Herein, we screened 12 clinical drugs, known to exhibit phototoxicity in patients, for their potential to interfere with the metabolism of (exogenous) FICZ and sensitize HaCaT keratinocytes to UVA-induced phototoxicity.</p><p><strong>Methods: </strong>The UV-VIS absorption of the drugs was determined, and their effect on CYP1A1 activity and FICZ/UVA-triggered apoptosis was assessed in immortalized and primary human keratinocytes using 7-ethoxyresorufin-O-deethylase (EROD) and caspase-3 activity assays. Moreover, the impact of the candidate drugs on the metabolic degradation of FICZ in cells (LC analysis) as well as on the generation of oxidative stress (MitoSOX assay, qPCR analyses) was investigated.</p><p><strong>Results: </strong>We identified two drugs, erlotinib and leflunomide, to sensitize human keratinocytes to FICZ/UVA-induced apoptosis by inhibiting CYP1A1 activity. Moreover, both drugs attenuated the metabolic breakdown of FICZ, enhanced the FICZ/UVA-triggered formation of mitochondrial superoxide anions, and increased heme oxygenase-1 (HMOX1) transcript levels, indicative of antioxidant defense activation.</p><p><strong>Conclusion: </strong>Disruption of FICZ metabolism may contribute to the phototoxicity of drugs.</p>","PeriodicalId":20123,"journal":{"name":"Photodermatology, photoimmunology & photomedicine","volume":"42 4","pages":"e70099"},"PeriodicalIF":2.7,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148101825","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Selective Involvement of Photoprotected Skin in an IL-36-Driven Pustular Eruption: A Possible Reverse Recall Phenomenon.","authors":"Evren Odyakmaz Demirsoy, Semanur Çakır Serinbaş, Dilek Bayramgürler, Busra Yaprak Bayrak, Rebiay Kıran","doi":"10.1111/phpp.70109","DOIUrl":"10.1111/phpp.70109","url":null,"abstract":"","PeriodicalId":20123,"journal":{"name":"Photodermatology, photoimmunology & photomedicine","volume":"42 4","pages":"e70109"},"PeriodicalIF":2.7,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13342481/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148405399","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hydroa Vacciniforme Lymphoproliferative Disorder With a Truncating KLF2 Variant Presenting as Benign Photodermatoses.","authors":"John Warner-Levy, Angelia Ong, Nina Farquharson, Jean Ayer","doi":"10.1111/phpp.70096","DOIUrl":"10.1111/phpp.70096","url":null,"abstract":"","PeriodicalId":20123,"journal":{"name":"Photodermatology, photoimmunology & photomedicine","volume":"42 3","pages":"e70096"},"PeriodicalIF":2.7,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13129242/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147778478","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Omalizumab Therapy Results in Defined Behavioural Changes and Improvements in Quality of Life in Solar Urticaria.","authors":"Donna Parkin, Elizabeth J Marjanovic, Mark D Farrar, Lesley E Rhodes, Kirsty J Rutter","doi":"10.1111/phpp.70088","DOIUrl":"10.1111/phpp.70088","url":null,"abstract":"<p><strong>Background: </strong>Solar urticaria is a rare photodermatosis in which exquisite photosensitivity can require extreme behavioural adaptations, resulting in a substantial impact on quality of life (QoL). Omalizumab therapy has been demonstrated to improve several clinical outcome measures, but the impact on behavioural measures is poorly understood. Our objectives were to examine daylight exposure behaviours and QoL measures pre- and post-omalizumab therapy.</p><p><strong>Methods: </strong>Daylight exposure diaries were completed by n = 5 patients with solar urticaria and n = 7 healthy participants during different seasons in England, UK (51.1-53.5^oN). These incorporated a range of measures, including time spent outdoors and clothing worn, and Dermatology Life Quality Index (DLQI) data were also collected.</p><p><strong>Results: </strong>Prior to omalizumab, patients spent less time outdoors in sunny vs. non-sunny conditions in spring (mean 10 vs. 29 min/day, p < 0.05) and less than healthy volunteers (44 min in sunny conditions/day). On omalizumab, patients increased their time outdoors in sunny conditions, reaching similar levels to healthy volunteers in spring (45 min/day) and further increasing to 85 min/day in summer. This was accompanied by fewer days with symptoms (symptoms on 75% days in spring pre-omalizumab vs. 26% days in summer on omalizumab), an apparent doubling of skin surface area exposure and substantial improvement in patients' QoL (mean past-year DLQI pre-omalizumab vs. past-week summer on omalizumab 22 vs. 5, p < 0.001).</p><p><strong>Conclusion: </strong>Omalizumab therapy was associated with behavioural changes that increase daylight exposure, accompanied by improved QoL. This study highlights the importance of considering a range of outcome measures in assessing response to therapy.</p>","PeriodicalId":20123,"journal":{"name":"Photodermatology, photoimmunology & photomedicine","volume":"42 3","pages":"e70088"},"PeriodicalIF":2.7,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13068439/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147654820","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Interplay of Skin Aging: Mitochondrial Stress and Ultraviolet Exposure.","authors":"Wanxing Liao, Yihao Wang, Yiping Wang, Junlin Liao, Nian Chen, Chiyu Jia, Li Zeng","doi":"10.1111/phpp.70089","DOIUrl":"10.1111/phpp.70089","url":null,"abstract":"<p><strong>Background: </strong>Skin photoaging, clinically characterized by wrinkles and hyperpigmentation, accounts for 80% of extrinsic aging. Chronic UV exposure drives this process via oxidative damage. However, its synergistic axis with mitochondrial dysfunction remains mechanistically elusive. This study aims to elucidate the mechanistic link between mitochondrial oxidative stress and UV-induced photoaging, focusing on reactive oxygen species overproduction as a central driver of cellular decline.</p><p><strong>Methods: </strong>Through integrative analysis of molecular pathways and experimental validation, we investigated mitochondrial dysfunction, ROS accumulation, and UV-induced damage in skin cells. Therapeutic interventions, including mitochondrial-targeted antioxidants (e.g., MitoQ) and protective agents, were tested to assess their efficacy in restoring mitochondrial integrity and mitigating oxidative stress.</p><p><strong>Results: </strong>UV radiation exacerbates mitochondrial dysfunction by inducing ROS overproduction, mtDNA mutations and membrane permeability alterations, creating a vicious cycle that accelerates skin aging. Conversely, mitochondrial oxidative stress amplifies UV-induced damage, promoting collagen degradation and apoptosis. Interventions targeting mitochondrial function, such as MitoQ and mesenchymal stem cell-derived exosomes, significantly reduced ROS levels, preserved membrane potential, and enhanced skin resilience. Notably, PINK1/Parkin-mediated mitophagy and STAT3/p53 pathways were identified as critical regulators of mitochondrial homeostasis during photoaging.</p><p><strong>Conclusion: </strong>This study clarifies the bidirectional relationship between mitochondrial stress and photoaging, highlighting ROS as a pivotal mediator. Restoring mitochondrial function via antioxidants or mitophagy enhancers offers actionable strategies to delay skin aging. These findings provide a foundation for novel anti-aging therapies with potential clinical and cosmetic applications.</p>","PeriodicalId":20123,"journal":{"name":"Photodermatology, photoimmunology & photomedicine","volume":"42 3","pages":"e70089"},"PeriodicalIF":2.7,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147623637","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"What Are the Histological Changes Corresponding to Clinical Effacement of Atrophic Acne Scars After Fractional Carbon Dioxide Laser Intervention-A Prospective Interventional Study in Skin of Color.","authors":"Abhinav Bansal, Kabir Sardana, Purnima Paliwal, Ananta Khurana, Savitha Sharath, Prisha Paliwal","doi":"10.1111/phpp.70086","DOIUrl":"10.1111/phpp.70086","url":null,"abstract":"<p><strong>Background: </strong>Pre-defined dose parameters of fractional carbon dioxide (Fr:CO₂) laser used for acne scars are not aligned with the histological depth achieved by the laser, which predicts scar improvement.</p><p><strong>Objectives: </strong>To evaluate the baseline histological depth and architecture of different acne scars and compare the histological changes and clinical improvement after Fr:CO₂ laser.</p><p><strong>Methods: </strong>We conducted a prospective study of atrophic acne scars-ice-pick, boxcar, or rolling. The patients were treated with three sessions of Fr:CO₂ laser with pre-determined dosimetry at 3-month intervals. Clinical evaluation was done at every visit using Echelle d'Evaluation clinique des Cicatrices d'acné (ECCA) scoring and individual atrophic acne scars count. Punch biopsy of predominant scars was taken pre- and 1-month post-treatment. The vertical depth of the scars was measured and histological changes in collagen and elastin were noted.</p><p><strong>Results: </strong>Forty-three patients with atrophic acne scars were included (27 boxcar, 9 ice-pick, and 7 rolling). Median histological depth of ice-pick, rolling and boxcar scars in pre-laser biopsies was 1606, 1546 and 1172 μm respectively, which significantly reduced to 1024 (p = 0.008), 858 (p = 0.018) and 746.5 μm (p < 0.0001) after the final laser session. Significant correlations were noted between acne scar reduction efficiency (ASRE%) and histological parameters at 7 months [ASRE% boxcar, increase in collagen grading (p < 0.05); ASRE% rolling, increased scar vascularization (p = 0.03) and ASRE% ice-pick, increased surrounding dermal elastin (p ≤ 0.05)].</p><p><strong>Conclusion: </strong>Fr:CO₂ laser intervention should be guided by scar-specific depth assessment, enabling optimal dosing and correlating this with histological changes would determine clinical improvement in acne scars.</p>","PeriodicalId":20123,"journal":{"name":"Photodermatology, photoimmunology & photomedicine","volume":"42 3","pages":"e70086"},"PeriodicalIF":2.7,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147575230","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy and Safety of 590 Nm and 590/630 Nm Light-Emitting Diode Therapy for Sensitive Skin: A Prospective Randomized Controlled Trial.","authors":"Xuanxuan He, Muyang He, Xuchao Wang, Chengfeng Zhang, Shanglin Jin","doi":"10.1111/phpp.70090","DOIUrl":"10.1111/phpp.70090","url":null,"abstract":"<p><strong>Objectives: </strong>Sensitive skin (SS) is a prevalent condition characterized by exaggerated sensory responses to environmental stimuli. Emerging evidence suggests that light-emitting diode (LED) therapy may alleviate SS symptoms by modulating inflammation and enhancing skin barrier function. This study aimed to evaluate the efficacy and safety of 590 nm yellow LED monotherapy versus the combination of 590 nm and 630 nm red-yellow LED therapy in SS patients.</p><p><strong>Methods: </strong>A single-center, prospective, randomized controlled trial was conducted on 30 volunteers diagnosed with SS. Participants were randomized into three groups: Group A (control, emollient only), Group B (590 nm yellow light, 10 mW/cm², 11 min, thrice weekly), and Group C (590/630 nm dual light, 30 mW/cm², 10 min, thrice weekly). Outcomes were assessed using the Laurent Misery sensitive scale-10 (SS-10) questionnaire, Thinkview imaging, transepidermal water loss (TEWL), pH value, erythema index (EI), melanin index (MI), and lactic acid sting test (LAST). Participants were evaluated at baseline and at follow-up visits during Weeks 2, 4, and 8.</p><p><strong>Results: </strong>Both LED treatment groups showed significant improvements in SS-10 scores compared to the control (p = 0.0025 and p < 0.0001). The 590 nm LED yellow light treatment markedly reduced EI (p = 0.0282), MI (p = 0.0109), TEWL (p = 0.0479) and showed superior improvements in LAST (p = 0.0013) compared with control, while 590/630 nm LED irradiation reduced lactic acid sting scores significantly compared with control (p = 0.0239). No adverse events were reported.</p><p><strong>Conclusions: </strong>LED light therapy, particularly 590 nm yellow light, is a safe and effective modality for alleviating SS symptoms, with dual-wavelength therapy showing complementary benefits.</p>","PeriodicalId":20123,"journal":{"name":"Photodermatology, photoimmunology & photomedicine","volume":"42 3","pages":"e70090"},"PeriodicalIF":2.7,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147634129","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}